AMRN:NASDAQ
Amarin Corporation PLC
$12.07
arrow_downward
-0.17%(-0.020) 1D
$12.07
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 6, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AMRN...
Open
$12.09
High
$12.28
Low
$11.83
Mkt. cap
260.44M
Avg. vol.
77.26K
Volume
44.00
52-wk high
$20.90
52-wk low
$11.83
EPS
-$1.30
Beta
0.76
Shares outstanding
21.12M
No. of employees
80
Open
$12.09
High
$12.28
Low
$11.83
Mkt. cap
260.44M
Avg. vol.
77.26K
Volume
44.00
52-wk high
$20.90
52-wk low
$11.83
EPS
-$1.30
Beta
0.76
Shares outstanding
21.12M
No. of employees
80
News stories
From web sources and news partners
Stock Titan
·
6 minutes ago
A Korean company completed quantum projects in materials and rail scheduling. A deal is expected to take it to Nasdaq.
PR Newswire
·
36 minutes ago
Fluence Energy (NASDAQ: FLNC) Faces Securities Class Action Amid Inability to Ramp Houston Facility - HBSS
Yahoo Finance
·
1 hour ago
AST SpaceMobile (ASTS) Completed Its First Direct Satellite To Smartphone Test In Canada
CNBC
·
51 minutes ago
AI trade driving stocks, but questions remain over rest of market
Profile
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid.
In July 2012, their lead-candidate drug named Vascepa received FDA-approval, competing against GlaxoSmithKline's Lovaza. Wikipedia
About Amarin Corporation PLC
CEO-
Employees80
FoundedMar 1, 1989
HeadquartersDublin, Leinster, Ireland
SectorBiotechnology
Websiteamarincorp.com